The mental healthcare system is in desperate need of innovation.

By harnessing the enormous potential of rapid acting psychedelics and digital technology we aim to deliver psychedelic therapies to all those who need them — where and when they need them.

An atai Life Sciences company

Viridia Life Sciences is a biotech company dedicated to developing N,N-Dimethyltryptamine in conjunction with digital therapeutics to deliver efficient, scalable treatments to patients on their own terms.

This pragmatic approach to simplifying DMT administration and the in-clinic treatment paradigm will help people access not only the neurogenic benefits of DMT, but also the personal insights that can accompany psychedelic-assisted psychotherapy… The impact for patients and their families may be transformative.

- Glenn Short

, CEO, Viridia Life Sciences

Our Team

The Viridia Team

Glenn
Short, Ph.D.

SVP, EARLY DEVELOPMENT

Srinivas Rao,
M.D., Ph.D.

Co-founder & Chief Scientific Officer

Florian
Brand

Co-founder & Chief Executive Officer

News

Contact

We'd love to hear from you.

Better mental healthcare is possible. Contact us to learn more about our mission and work.

[email protected]

Follow us on socials







    This site is protected by reCAPTCHA and the Google
    Privacy Policy and
    Terms of Service apply.

    JOIN THE ATAI #INSIGHTNETWORK

    Want to learn more?
    Sign up for weekly updates.

    Email
    submit